Home » About SARC
SARC (Sarcoma Alliance for Research through Collaboration) is a non-profit organization dedicated to the development and support of research for the prevention, treatment, and cure of sarcomas – a cancer of the bone and connective tissue of the body.
SARC was founded by a small group of physicians specializing in sarcoma. Recognizing the value of pooling their intellectual and patient resources, a core group of medical and pediatric sarcoma experts at five major medical facilities formed SARC in 2003 to conduct innovative and rigorous sarcoma research to advance the care of their patients. Today, the leadership of SARC consists of respected sarcoma physicians across the country, working together to develop new strategies to improve the outcomes for sarcoma patients.
SARC directly develops, sponsors, and manages research projects for pediatric and adult sarcomas. We lead domestic and international collaborative discovery, translational research, and clinical trials – and meet twice annually to discuss the latest therapies and concepts for new clinical trials. We are an open and transparent organization that welcomes ideas and encourages involvement from all.
We understand that finding experienced sarcoma care without delay is the one of the biggest challenges for sarcoma patients and their families. SARC has developed a suite of patient resources – the Sarcoma Centers Directory, Sarcoma Reference Guide, Patient Advocacy Directory, and Helpline – to connect families with the expert care that they need.
Other important SARC initiatives include the Career Development Award to foster innovative research by new investigators as well as resources for researchers including the SARC Biospecimen Bank, Imaging Resources, and Clinical Data Repository.
In 2012, SARC received a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). This SARC Sarcoma SPORE grant provided $11.5 million over five years in support of laboratory and clinical scientists working collaboratively on sarcoma translational research.